Rinvoq, Gazyva, and Sotyktu Emerge as Front-Runners for Lupus Care
Biologic use for systemic lupus erythematosus (SLE) is increasing, with nearly 40% of moderate-to-severe SLE patients in the U.S....
Qu Biologics’ Immunomodulator Study in Elderly
Qu Biologics has completed enrollment for its RESILIENCE Study, a Phase 2 clinical trial testing QBKPN SSI, a novel...
Clearmind Medicine starts the leading Israeli Clinical site
Clearmind Medicine Inc. announced the successful initiation of a clinical trial site at Tel Aviv Sourasky Medical Center (TASMC)...
Windward Bio Launches Global Phase 2 Asthma Trial of WIN378
Windward Bio has launched its Phase 2 POLARIS clinical trial to assess the long-acting dosing of WIN378, an anti-TSLP...
Aquablation® Prostate Cancer Trial: Water IV Procedures Completed
PROCEPT BioRobotics announced the successful completion of three prostate cancer procedures using Aquablation therapy in an ambulatory surgery center...
Recognify’s Phase 2b Trial of Inidascamine Falls Short on Primary Endpoint in CIAS
In a 242-patient Phase 2b trial for cognitive impairment associated with schizophrenia (CIAS), inidascamine (formerly RL-007) failed to meet...
Briacell Announces Clinical Data at ESMO 2025
BriaCell Therapeutics Corp. will present two clinical data posters at the European Society for Medical Oncology (ESMO) Congress 2025...
Liminatus Pharma Evaluates Digital Asset Strategy
Liminatus Pharma, a preclinical-stage biopharmaceutical company focused on cancer immunotherapy development, has partnered with Digital Offering LLC to explore...
Cervomed to Present New Phase 2b Rewind-LB Study Data at AAIC 2025
CervoMed (NASDAQ: CRVO) will share 32-week primary endpoint results from the extension phase of its Phase 2b RewinD-LB study...
Anti-Siglec-15 Therapy Improves Bone Health in Osteogenesis Imperfecta Mice
NextCure, Inc. announced preclinical data for NC605, an anti-Siglec-15 antibody, showing improved bone microarchitecture and reduced fractures in an...